化学
癌症研究
成纤维细胞生长因子受体4
成纤维细胞生长因子受体
成纤维细胞活化蛋白
癌症
受体酪氨酸激酶
受体
癌细胞
作者
Hang Chen,Katherine K. Slemmons,Heather Ha,Robert F. Stanley,Qian Cai,Irene Yuan,Lee J. Helman,Ping Cao
出处
期刊:Molecular Cancer Therapeutics
[American Association for Cancer Research]
日期:2019-12-01
卷期号:18
标识
DOI:10.1158/1535-7163.targ-19-c072
摘要
Hepatocellular carcinoma (HCC) accounts for 65% of all cases of liver cancers, ranking the 6th most common cancer and the 2nd cause of cancer mortality. HCC has more than 700,000 new cases/year and 600,000 deaths/year. Sorafenib is currently the standard of care for advanced disease, provides a response rate of ~2% and median survival Citation Format: Hang Chen, Katherine Slemmons, Heather Ha, Robert Stanley, Qian Cai, Irene Yuan, Lee Helman, Ping Cao. Discovery of highly potent and selective covalent inhibitors of FGFR4 [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C072. doi:10.1158/1535-7163.TARG-19-C072
科研通智能强力驱动
Strongly Powered by AbleSci AI